• Viral infections

Emtriva Generic Name & Formulations

General Description

Emtricitabine 200mg; caps.

Pharmacological Class

Nucleoside analogue (reverse transcriptase inhibitor).

How Supplied

Caps—30; Soln—170mL


Emtriva Indications


HIV-1 infection, in combination with other antiretroviral agents.

Emtriva Dosage and Administration


≥18yrs: 200mg once daily. Renal impairment (CrCl 30–49mL/min): 200mg every 48hrs; (CrCl 15–29mL/min): 200mg every 72hrs; (CrCl <15mL/min or dialysis): 200mg every 96hrs.


<3mos: use oral soln. 3mos–17yrs (≤33kg): use oral soln; (>33kg): 200mg once daily. Renal impairment: reduce dose or prolong dosing interval (see full labeling).

Emtriva Contraindications

Not Applicable

Emtriva Boxed Warnings

Boxed Warning

Posttreatment exacerbation of hepatitis B.

Emtriva Warnings/Precautions


Not for treating chronic HBV infection; test for HBV before starting therapy and closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted. Suspend therapy if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Renal impairment. Pregnancy (Cat.B). Nursing mothers: not recommended.

Emtriva Pharmacokinetics

See Literature

Emtriva Interactions


Avoid concomitant drugs that contain emtricitabine or lamivudine (eg, fixed dose combination products).

Emtriva Adverse Reactions

Adverse Reactions

Headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, rhinitis; new onset or worsening renal impairment, immune reconstitution syndrome; also children: skin hyperpigmentation.

Emtriva Clinical Trials

See Literature

Emtriva Note


Register pregnant patients exposed to emtricitabine by calling (800) 258-4263.

Emtriva Patient Counseling

See Literature